Pediatric Nephrology

, Volume 29, Issue 3, pp 477–480 | Cite as

Use of eculizumab and plasma exchange in successful combined liver–kidney transplantation in a case of atypical HUS associated with complement factor H mutation

  • Ha Tran
  • Abanti Chaudhuri
  • Waldo Concepcion
  • Paul C. Grimm
Brief Report



Atypical hemolytic uremic syndrome (aHUS) evolves into end-stage renal failure in nearly half of affected patients and is associated with defective regulation of the alternative complement pathway. Patients with a complement factor H (CFH) mutation have a 30–100% risk of graft loss due to aHUS recurrence or graft thrombosis. Since CFH is produced predominantly by the liver, combined liver–kidney transplant is a curative treatment option. One major unexpected risk includes liver failure secondary to uncontrolled complement activation. We report a successful combined liver–kidney transplantation with perioperative plasma exchange and use of the humanized anti-C5 monoclonal antibody eculizumab.

Case Diagnosis/Treatment

An 11-month-old female presented with oliguric renal failure after 3 weeks of flu-like symptoms in the absence of diarrhea. Following the identification of Escherichia coli 0157:H7 in her stool, she was discharged home on peritoneal dialysis with a diagnosis of Shiga toxin-associated HUS. Three months later, she developed severe anemia, thrombocytopenia, and neurological involvement. aHUS was diagnosed and confirmed, and genetic testing revealed a mutation in CFH SCR20. Once donor organs became available, she received preoperative plasma exchange followed by eculizumab infusion with intra-operative fresh frozen plasma prior to combined liver–kidney transplant. At 19 months post-transplant, she continues to have excellent allograft and liver function without signs of disease recurrence.


Perioperative use of eculizumab in conjunction with plasma exchange during simultaneous liver–kidney transplant can be used to inhibit terminal complement activity, thereby optimizing successful transplantation by reducing the risk of graft thrombosis.


Atypical HUS Eculizumab Combined liver kidney transplant Factor H mutation Plasma exchange 


  1. 1.
    Saland JM, Ruggenenti P, Remuzzi G, Consensus Study G (2009) liver–kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 20:940–949PubMedCrossRefGoogle Scholar
  2. 2.
    Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P (2011) Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488–1494PubMedCrossRefGoogle Scholar
  3. 3.
    Loirat C, Noris M, Fremeaux-Bacchi V (2008) Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 23:1957–1972PubMedCrossRefGoogle Scholar
  4. 4.
    Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L (2001) Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138:412–417PubMedCrossRefGoogle Scholar
  5. 5.
    Zimmerhackl LB, Scheiring J, Prufer F, Taylor CM, Loirat C (2007) Renal transplantation in HUS patients with disorders of complement regulation. Pediatr Nephrol 22:10–16PubMedCrossRefGoogle Scholar
  6. 6.
    Davin JC, Strain L, Goodship TH (2008) Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 23:1517–1521PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Fremeaux-Bacchi V, Steiger J (2009) Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 24:3548–3551PubMedCrossRefGoogle Scholar
  8. 8.
    Wilson C, Torpey N, Jaques B, Strain L, Talbot D, Manas D, Goodship T (2011) Successful simultaneous liver–kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 58:109–112PubMedCrossRefGoogle Scholar
  9. 9.
    Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W (2010) Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Eng J Med 362:1746–1748CrossRefGoogle Scholar
  10. 10.
    Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55:708–711PubMedCrossRefGoogle Scholar
  11. 11.
    Albertazzi V, Bonucchi D, De Amicis S, Americo C, Ghiandai G, Cappelli G (2010) A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report. Transplant Proc 42:1352–1354PubMedCrossRefGoogle Scholar
  12. 12.
    Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M (2005) Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 5:1146–1150PubMedCrossRefGoogle Scholar
  13. 13.
    Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH (2006) Favorable long-term outcome after liver–kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 6:1948–1952PubMedCrossRefGoogle Scholar
  14. 14.
    De Vries B, Matthijsen RA, Wolfs TG, Van Bijnen AA, Heeringa P, Buurman WA (2003) Inhibition of complement factor C5 protects against renal ischemia–reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 75:375–382PubMedCrossRefGoogle Scholar
  15. 15.
    Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH (2000) Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 105:1363–1371PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders ME, Schaapherder AF, Kooten C (2013) Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation 95:816–820PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2013

Authors and Affiliations

  • Ha Tran
    • 1
  • Abanti Chaudhuri
    • 1
  • Waldo Concepcion
    • 1
  • Paul C. Grimm
    • 1
  1. 1.Stanford UniversityStanfordUSA

Personalised recommendations